Ciltacabtagene Autoleucel

DRUG5 trials

Conditions

AL AmyloidosisMultiple MyelomaMyeloma MultiplePlasma Cell LeukemiaRecurrent Multiple MyelomaRefractory Multiple MyelomaRelapse Multiple MyelomaSmoldering Multiple Myeloma

Phase 1

Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function

RecruitingNCT06623630

Washington University School of MedicineMultiple Myeloma

Start: 2024-12-04End: 2028-05-31Target: 16Updated: 2026-03-11

Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma

RecruitingNCT07093554

Medical College of WisconsinRefractory Multiple Myeloma, Relapse Multiple Myeloma

Start: 2025-12-02End: 2028-01-01Target: 31Updated: 2026-01-05

Phase 2

CAR- PRISM (PRecision Intervention Smoldering Myeloma)

Active, not recruitingNCT05767359

Dana-Farber Cancer InstituteMultiple Myeloma, Smoldering Multiple Myeloma

Start: 2023-04-19End: 2040-01-15Updated: 2026-03-12

Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

RecruitingNCT06940297

Mayo ClinicRecurrent Multiple Myeloma, Refractory Multiple Myeloma

Start: 2025-06-23End: 2031-08-15Target: 44Updated: 2026-02-06

Unknown Phase

The Norwegian Immunotherapy in Multiple Myeloma Study

RecruitingNCT06855121

St. Olavs HospitalAL Amyloidosis, Myeloma Multiple, Plasma Cell Leukemia

Start: 2025-01-15End: 2037-12-01Target: 400Updated: 2025-03-03

Related Papers

Abstract 6475: Myeloma cells with therapy-induced senescence-like phenotype have increased resistance to killing by T cell directed therapies

Cancer Research2026-04-03

Abstract 6467: Myeloma cells with therapy-induced senescence-like phenotype are associated with resistance to CAR-T therapy